Drug intelligence / Profile preview

silodosin + alfuzosin

Development stage: Unknown
Lead developer: Golden Square Lab
Modality: Small Molecules
Administration: Oral

Overview

Silosquare + Alfusquare is a combination pharmaceutical product marketed by Golden Square Lab for the treatment of benign prostatic hyperplasia (BPH). The formulation consists of two alpha-1 adrenergic receptor antagonists: silodosin and alfuzosin. Silodosin is a highly uroselective antagonist with high affinity for the alpha-1A receptor subtype, while alfuzosin is a non-selective alpha-1 blocker. Together, these agents work to relax the smooth muscle in the prostate and bladder neck, thereby improving urinary flow and reducing the obstructive symptoms associated with BPH.

Brand names: Silosquare + AlfusquareSilosquare-Alfusquare
Other names: silodosin + alfuzosin

Targets

ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on silodosin + alfuzosin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on silodosin + alfuzosin.

Explore the full profile